The downregulation or silencing of the NPRL2 gene via aberrant splicing transcripts, multiple exon deletions or intragenic homozygous deletions, has been observed in renal cell carcinoma, lung cancer and other types of cancer and cancer-derived cell lines in humans, suggesting that NPRL2 may be a tumor suppressor, the inactivation of which may promote tumori-genesis (4–8). Here, NPRL2 is linked to neoplasm.